NMUS - Nemus Bioscience, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD

Nemus Bioscience, Inc.

600 Anton Boulevard
Suite 1100
Costa Mesa, CA 92626
United States

Full Time Employees3

Key Executives

NameTitlePayExercisedYear Born
Dr. Brian S. MurphyCEO, Chief Medical Officer & Director448.85kN/A1958
Dr. Avtar S. DhillonExec. ChairmanN/AN/A1962
Mr. Douglas A. CesarioChief Financial OfficerN/AN/A1975
Ms. Wendy CunningVP of Bus. OperationsN/AN/AN/A
Amounts are as of December 31, 2017 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Nemus Bioscience, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of cannabinoid-based therapeutics. The company's product candidates in preclinical stage include NB1111 for the treatment of glaucoma; NB1222 used for treating chemotherapy induced nausea and vomiting; and NB3111 for the treatment of methicillin-resistant staphylococcus aureus. Its products under research comprise NB2111 for use in treating chemotherapy induced peripheral neuropathy; and NB2222 for the treatment of uveitis, dry eye syndrome, macular degeneration, and diabetic retinopathy. Nemus Bioscience, Inc. has a license agreement with the University of Mississippi to research, develop, and commercialize products for the treatment of infectious diseases. The company was founded in 2012 and is headquartered in Costa Mesa, California.

Corporate Governance

Nemus Bioscience, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.